Table 1 (abstract P257). Demographic data, SDI and its association comparison across various cross-sectional studies
From: Proceedings of the 27th European Paediatric Rheumatology Congress (PReS 2021)
Author. citation | Ravelli et al. Arthritis Care Res. 2003 Aug 15;49(4):501-7 | Lilleby et al. Clin Exp Rheumatol. 2005;23(2):261-9 | Brunner et al. Arthritis Rheumatol. 2008 Feb;58(2):556-62 | Salah et al. Rheumatol Int. 2009 Oct 1;29(12):1463 | Sit JK et al. Pediatric Rheumatol. 2018 Dec 1;16(1):56 | Our study 2019 |
|---|---|---|---|---|---|---|
Sample size (N) | 387 | 71 | 67 | 148 | 59 | 50 |
Gender (Females %) | 85.27 | 76 | 85 | 69.6 | 84.8 | 74 |
SDI >0 (%) | 50.5 | 61 | 56.1 | 43.9 | 33.9 | 28 |
Median SDI (IQR) | 1 (NM) | 1 (NM) | 1.7 (2.67)* | 0.93 (1.37)* | 0 (NM) | 0 (0-1) |
Median age at diagnosis (years) (IQR) | 12.4 (NM) | 14.5 (NM) | 12.7 (2.5)* | 10.5 (2.75)* | 13 (12-15) | 11.8 (10-13.6) |
Median age at study visit (years) (IQR) | 16.6 (NM) | 26.5 (NM) | NM | 17.1 (3.8)* | NM | 18.8 (15.8-20.6) |
Median diagnostic delay (months) (IQR) | NM | NM | NM | NM | NM | 5 (2-10) |
Median disease duration (years) (IQR) | 4.6 (NM) | 9.8 (NM) | NM | 6.57 (3.59)* | 7.8 (5.5-10.1) | 6.6 (4.4-8.6) |
Damage associations | Disease duration, NPS,CYC | Disease duration, Hypertension, Steroids | Disease activity, Steroids | Diagnostic criteria, age at onset, disease duration, NPS | Age at diagnosis, NPS, major organs involved, disease flares /infection | NPS, Steroids (>0.3mg/kg/day), growth failure |